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 Abstract. Hepatic Veno-Occlusive Disease (VOD) is a potentially severe complication of 
hematopoietic stem cell transplantation (HSCT). Here we report two patients receiving an 
allogeneic HSCT who developed late onset VOD with atypical clinical features.  The  two  
patients presented with only few risk factors, namely, advanced acute leukemia, a myeloablative 
busulphan-containing regimen and received grafts from an unrelated donor. The first patient 
did not experience painful hepatomegaly and weight gain and both patients showed only a mild 
elevation in total serum bilirubin level. Most importantly, the two patients developed clinical 
signs beyond day 21 post-HSCT. Hepatic transjugular biopsy confirmed the diagnosis of VOD. 
Intravenous defibrotide was promptly started leading to a marked clinical improvement. Based 
on our experience, liver biopsy may represent a useful diagnostic tool when the clinical features 
of VOD are ambiguous. Early therapeutic intervention with defibrotide represents a crucial 
issue for the successful outcome of patients with VOD. 
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Introduction. Veno-occlusive disease (VOD), 
also known as sinusoidal obstruction syndrome 
(SOS), is a potentially life-threatening 
complication of hematopoietic stem cell 
transplantation (HSCT).
1
 The diagnosis of VOD is 
primarily based on clinical criteria defined almost 
20 years ago, including the triad of painful 
hepatomegaly, jaundice and fluid retention.
2-4
 This 
observation could at least partially explain the 
highly variable incidence of VOD reported in the 
literature, ranging from 8% to 14%. VOD usually 
develops within 20-30 days after HSCT. However, 
few cases of late-onset VOD have been reported.
5
 
According to this observation, the European  
Group for Bone marrow Transplantation (EBMT) 
recently endorsed the revised diagnostic criteria 
 Table 1. Criteria for definition of Late-Onset VOD (according to “The new classification from the European Society for Blood and Marrow 
Transplantation”, BMT 2016).6 
 
Late Onset VOD 
(> 21 Days after HSCT) 
Classical VOD/SOS beyond day 21: Bilirubin > 2 mg/dL and two of the following criteria: 
Painful hepatomegaly OR weight gain > 5% OR ascites 
OR 
Histologically proven VOD/SOS 
OR 
Two or more of the following criteria: Bilirubin > 2 mg/dL (or 34 micromols/L) OR 
Painful hepatomegaly OR weight gain > 5% OR ascites 
moreover, hemodynamical or/and ultrasound evidence of VOD/SOS 
Abbreviations: EBMT =European Society for Blood and Marrow Transplantation; SOS =sinusoidal obstruction syndrome; VOD =veno- 
occlusive disease. These symptoms/signs should not be attributable to other causes. 
 
for VOD/SOS, which now include either a 
classical form of VOD and a late-onset variant 
(Table 1).
6
 
Here we describe two HSCT recipients who 
developed late-onset VOD with atypical clinical 
features. 
 
Case 1. A 55-year-old male was diagnosed with 
acute myeloid leukemia in May 2015. He failed to 
achieve the complete remission (CR) after two 
induction chemotherapy courses with high dose 
cytarabine, idarubicin and etoposide and salvage 
treatment with fludarabine and idarubicin. The 
presence of a matched unrelated donor in the 
International Marrow Donor Registries prompted 
us to proceed with an allogeneic HSCT following 
a “sequential” conditioning regimen. The patient 
was initially treated with mitoxantrone (6 
mg/sqm/day), etoposide (80 mg/sqm/day) and 
cytarabine (1 g/sqm/day for four days), followed, 
10  days  later,  by  a  conditioning  which included 
i.v. Busulphan (3.2 mg/kg/day) and Fludarabine 
(50 mg/mq/day) for four days and the infusion of 
mobilized donor peripheral blood stem cells 
(PBSC). Graft-vs.-Host disease (GVHD) 
prophylaxis consisted of anti-thymocyte globulin, 
cyclosporine and a short course of methotrexate. 
An absolute neutrophil count higher than 0.5 x 
10
9
/L and a platelet count higher than 20.000/mcl 
were achieved on day + 13. On day + 33, the 
patient suddenly showed abdominal distension 
with ascites, increase in liver enzymes (AST 391 
U/l, ALT 245 U/l) and in total bilirubin (1.2 
mg/dL) and signs of liver and renal insufficiency 
(INR  1.43;  aPTT  65.5’’;  serum  creatinine value 
3.04 mg/dL). The patient did not present either 
painful hepatomegaly or weight gain >2%, or 
signs of intestinal or cutaneous acute GVHD. Viral 
hepatitis was ruled out by microbiological testing. 
Ultrasonography showed normal liver 
parenchyma, regular biliary tract, moderate 
splenomegaly (15 cm) with ascites and right 
pleural effusion. Doppler exam ruled out portal 
vein thrombosis but showed increased portal vein 
diameter (10 mm) suggestive of portal 
hypertension. Paracentesis was performed and 
showed presence of transudate fluid (serum 
albumin = 3 mg/dL, ascites albumin 1.5 mg/dL, 
serum-ascites albumin ratio = 2). 
Given that clinical symptoms and laboratory 
tests did not allow to discriminate between VOD, 
acute GVHD, toxicity or infective causes, a 
hepatic transjugular biopsy was performed. 
Histology studies showed the expansion of the 
hepatic sinusoid spaces, with gaps in the 
sinusoidal barrier which were highly suggestive of 
hepatic VOD in the light of the involvement of 
zone 3, zone 2 and partially zone 1 of the hepatic 
acinus (Figure 1). 
Intravenous defibrotide was started at the dose 
of 6.25 mg/kg QID on day +37 for 21 days, along 
with ancillary therapy including albumin 
replacement and low dose diuretics; nonsteroids 
have been administered. Two-three days after the 
beginning of defibrotide, the patient showed a 
marked clinical improvement with gradual 
improvement and normalization of liver and renal 
function tests (Figure 2). One week after the 
beginning of defibrotide, the patient developed 
hemorrhagic cystitis, treated with 2 bladder 
instillations of hyaluronic acid which led to 
progressive improvement and complete resolution 
upon regular discontinuation of defibrotide after 
21 days of treatment. Hemorrhagic cystitis did not 
require an earlier discontinuation of defibrotide. 
During the treatment course, platelet count 
  
Figure 1. Images of hepatic transjugular biopsy: in the middle, the red arrows showed the expansion of hepatic sinusoid spaces, on the right 
the figure showed a centrilobular vein. 
 
Figure 2. Diagnostic interventions with liver function profile from clinical onset of VOD until resolution, and treatment of VOD in case 1. 
 
remained low between 10.000 to 20.000/mmc 
even with transfusion support. The patient was 
discharged on day +76 in complete remission of 
his underlying disease on low doses of 
cyclosporine. 
 
Case 2. A 46-year old male was diagnosed with 
acute myeloid leukemia - normal karyotype, 
FLT3, and NPM1 wild-type - in May 2015. The 
patient was treated with idarubicin plus etoposide 
and cytarabine with no hematologic response. 
Complete remission was subsequently obtained 
with a course of high-dose cytarabine, followed 
consolidation with 2 additional courses of high- 
dose cytarabine. An unrelated marrow donor 
search was started and a partially (one-antigen 
mismatched) HLA-matched donor was identified. 
The patient received mobilized donor HSCT after 
a conditioning regimen with Thiotepa (5 
mg/kg/day for 2 days), Busulphan (3,2 mg/kg/day 
for 3 days) and Fludarabine (50 mg/kg/day for 3 
days). GvHD prophylaxis included cyclosporine, 
short course methotrexate, and anti-thymocyte 
globulin ATG (2,5 mg/kg/day for 3 days). 
Neutrophil and platelet engraftment occurred on 
day +14 and +12 respectively. The patient 
experienced a transient skin rash suggestive of 
grade I acute GVHD on day +19, and 3 episodes 
of CMV reactivation on days +27, +43 and +82 
successfully treated with preemptive 
valganciclovir and immunoglobulins. 
The patient was readmitted because of severe 
anemia and thrombocytopenia (Hb 5,8 gr/dl; 
platelet 5000/ul) and complaints of right 
abdominal pain with melena on day +89. 
Significant weight gain (+7 kg) along with 
abdominal distension and anasarca were observed 
on day +91. Laboratory exams showed total 
bilirubin 3,30 mg/dl, AST/ALT 140/164 UI , GGT 
725 Ul, INR 1,7; aPTT 41,3”, serum creatinine 2,0 
mg/dl; platelet count was 20.000/mmc. An 
abdominal CT scan revealed ascites and hepatic 
  
Figure 3. Diagnostic interventions with liver function profile from clinical onset of VOD until resolution, and treatment of VOD in case 2. 
 
veins compression. Transjugular measurement of 
the hepatic venous pressure gradient showed 
severe sinusoidal portal hypertension with a 
significant transhepatic/caval gradient diagnostic 
for severe VOD. Transjugular liver biopsy showed 
sinusoidal dilation and bleeding with erythrocytes 
in the Disse space, and significant iron overload. 
Histology studies were consistent with severe 
VOD. 
Intravenous defibrotide was promptly started at 
the dose of 6.25 mg/kg QID for 22 days. 
Ancillary therapy included plasma and red 
blood cells transfusions, no steroid have been 
administered. A complete and sustained response 
was achieved. The patient was discharged on day 
+121. The patient is currently alive, 188 days after 
transplant, with normal liver function, no evidence 
of GvHD, or any other relevant clinical 
complication. A bone marrow aspirate showed 
complete remission of his underlying disease. 
 
Discussion. Recognition of potential risk factors 
for VOD is a key point for early diagnosis and 
prompt therapeutic intervention. Recently, the 
EBMT group has categorized these risk factors as 
transplant-, hepatic-, patient- and disease-related.
7-
 
9 
Interestingly, our patients presented with only a 
few risk factors, namely, advanced acute  
leukemia, a myeloablative busulphan-containing 
conditioning  and  an  unrelated  donor. Moreover, 
both patients did not show the typical clinical 
VOD features described by the Seattle
2-3
 and 
Baltimore
4
 criteria. In particular, the first patient 
did not experience either painful hepatomegaly or 
weight gain, and only a mild elevation in total 
serum bilirubin level was observed after the 
development of ascites, while the second patient 
showed only mild hyper-bilirubinemia concurrent 
with painful hepatomegaly and significant weight 
gain. Most importantly, both patients developed 
clinical signs beyond day 21 post-HSCT (on days 
+33 and +89 respectively). In this respect, it 
should be emphasized that the EBMT consensus
6
 
has now recognized the existence of a “late onset” 
VOD, defined with less stringent diagnostic 
criteria and where hyper-bilirubinemia should no 
longer be mandatory for diagnosis. Overall, in 
these two patients, the short time between the 
onset of clinical symptoms and the final diagnosis, 
and the higher than 5 fold increase in 
transaminases combine to diagnose a severe form 
of VOD by the new EBMT criteria (Table 1) 
Both the British guidelines
10
 and the EBMT 
recommendations indicate that liver biopsy should 
be reserved for those patients in whom the 
diagnosis of VOD is unclear, and there is an 
urgent need to rule out other possible causes of 
liver dysfunction. In our experience, a transjugular 
liver biopsy was safe despite severe 
thrombocytopenia and, most importantly, was 
 conclusive for the diagnosis of VOD ruling out 
drug toxicities, viral infections, sepsis or 
GVHD.
11-13
 In keeping with our findings, Kis et al. 
reported only 1.8% of major complications during 
166 transjugular liver biopsies.
14
 
Defibrotide is the only agent approved for the 
treatment of VOD in Europe. Defibrotide has been 
shown to have antithrombotic and anti- 
inflammatory properties and may promote 
revascularization inducing endothelial cell 
proliferation and angiogenesis.
15
 In our patients, 
the combination of clinical features and histology 
studies prompted us to start defibrotide only a few 
days after the onset of symptoms. Our experience 
strengthens the observation reported by 
Richardson et al.,
16
 that the timely administration 
of defibrotide may represent a crucial issue for the 
successful outcome of patients with VOD. Sixty % 
of patients were alive when defibrotide was started 
within 2 days from the onset of symptoms as 
compared with 14% when treatment was delayed 
and started after 7 days. Similar results were 
reported by Corbacioglu et al.
17
 Our patients began 
defibrotide treatment within 7 days from the onset 
of symptoms but within 1 day from the 
histological diagnosis. They did not fall exactly in 
the early treatment category. Nevertheless, 
defibrotide has been initiated within 7 days, 
representing the crucial threshold to achieve a 
good outcome. Phase 2 and 3 studies
18-22
 
demonstrated that defibrotide was generally well 
tolerated with manageable toxicity. Hemorrhagic 
complications were reported as the most frequent 
adverse event. Hemorrhagic cystitis, which 
occurred in one of our patients, is a common 
complication in HSCT recipients. Though other 
causes may have been involved, we could not rule 
out that it may have been related to defibrotide 
treatment given its prompt resolution upon drug 
discontinuation.
22
 
 
Conclusions. VOD should be considered in the 
differential diagnosis of HSCT recipients who 
present with unexplained liver injuries, ascites 
and/or MOF. Liver biopsy may represent a useful 
diagnostic tool when the clinical criteria for VOD 
are not entirely fulfilled. Early therapeutic 
intervention with defibrotide may improve the 
clinical outcomes of these patients. 
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